Maintaining a healthy life style is on the rise. In this regard, people search for products that can enhance health and are driven towards natural products that are not always as save as thought to be. For example, products based on the Cannabis Sativa plant, such as CBD or Cannabidiol, gain popularity and, with this, their consumption rises. Their composition and, herewith, their risks are not entirely known, so new methods need to be implemented to analyse their cannabinoid content and screen for other components and/or contaminants present in these products.
Products that claim only to have Cannabidiol (CBD) as an active compound without any delta 9-Tetrahydrocannabinol (Δ9-THC), are given a wide range of health claims. Currently, these Cannabis Sativa based products are only screened for their Δ9-THC and CBD dosage. Following the drug and consumption law, they may contain a Δ9-THC value < 0.2%.
To evaluate the risk of these products, more elaborate methods are needed. These methodologies should be able to analyse the main cannabinoids within different matrices. Also methodologies to screen for the presence of other components or contaminants are necessary.
The aim of this project is to develop and implement analytical methods for the characterisation of commercial CBD-products. The focus is set on the standardisation of sample preparation steps and the validation of the analysis according to the ISO17025 guidelines. Moreover, this projects goal is to gain an overall picture of the composition of the products, namely the cannabinoid composition, illegal substances, organic contaminants, matrix components, etc.